Treatment of Patients With Diabetic Kidney Disease

Sponsor
Assiut University
Study ID
NCT06187493
Status
Unknown

Conditions

  • Diabetic Kidney Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • lisinopril, enalapril — DRUG
    1. Both arms should aim to achieve optimal blood pressure control, typically defined as a systolic blood pressure below 130 mmHg and a diastolic blood pressure below 80 mmHg. This can be achieved through lifestyle modifications, additional medications, or a combination of both. 2. Maintaining good glycemic control is also important for both arms. This can be achieved through diet, exercise, and diabetes medications. 3. Both arms may also receive other supportive care measures for DKD, such as protein restriction, dietary counseling, and management of other co-morbidities like anemia and hyperlipidemia.
  • dapagliflozin, empagliflozin — DRUG
    1. Both arms should aim to achieve optimal blood pressure control, typically defined as a systolic blood pressure below 130 mmHg and a diastolic blood pressure below 80 mmHg. This can be achieved through lifestyle modifications, additional medications, or a combination of both. 2. Maintaining good glycemic control is also important for both arms. This can be achieved through diet, exercise, and diabetes medications. 3. Both arms may also receive other supportive care measures for DKD, such as protein restriction, dietary counseling, and management of other co-morbidities like anemia and hyperlipidemia.

Study Details

Due to irrespective of the limitations associated with estimated glomerular filtration rate (eGFR), it is crucial to develop new treatments that can effectively address these concerns. So, this study aimed to compare the effectiveness of SGlT2i versus ACEi in the progression of diabetic kidney disease including progression of albuminuria. Doubling of serum creatinine and need for renal replacement therapy

Key Dates

Start date
Jan 1, 2024
Status verified
Dec 2023
Primary completion
Jan 31, 2025
Completion
Dec 31, 2025

Study Design

Enrollment
70 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Other: Efficacy of ACEi
    Patients receive an ACEi medication, such as lisinopril, enalapril, or ramipril. These drugs work by blocking the production of angiotensin II, a hormone that can constrict blood vessels and raise blood pressure.
  • Other: Efficacy of SGLT2i
    Patients receive an SGLT2i medication, such as dapagliflozin, empagliflozin, or canagliflozin. These drugs work by preventing the kidneys from reabsorbing glucose from the urine, leading to lower blood sugar levels and potentially reducing the risk of kidney damage.

Primary Outcome Measure

prevention of the development of DKD and alter its natural progression. [ Time Frame: baseline≥3 months-year ]

Central Contacts

Related Studies